Recent Advances in the Adjuvant Therapy of Breast Cancer

Castiglione-Gertsch M. , Price K.N. , Nasi M.L. , Lindtner J. , Erzen D. , Crivellari D. , Veronesi A. , Fey M. , Pagani O. , Collins J. , Forbes J. , Rudenstam C-M. : Is the addition of adjuvant chemotherapy always necessary in node-negative postmenopausal breast cancer patients who receive tamoxifen? First results of IBCSG trial IX. Proc. Am. Soc. Clin. Oncol., 19: A281, 2000.

Davidson N. , O'Neill A. , Vukov A. , Osborne C.K. , Martino S. , White D. , Abeloff M.D. for ECOG, SWOG and CALGB: Effect of chemohormonal therapy in premenopausal, node positive, receptor positive breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial. Proc. Am. Soc. Clin. Oncol., 18: A249, 1999.

Early Breast Cancer Trialist's Collaborative Group: Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet, 348: 1189–1196, 1996.

Ejlertsen B. , Dombernowsky P. , Mouridsen H.T. , Kamby C. , Kjaer M. , Rose C. , Andersen K.W. , Jensen M.B. , Bengtsson N.O. , Bergh J. : Comparable effect of ovarian ablation and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients. Proc. Am. Soc. Clin. Oncol., 18: A248, 1999.

Engelsman E. , Klijn J.C. , Rubens R.D. , Wildiers J. , Beex L.V. , Nooij M.A. , Rotmensz N. , Sylvester R. : Classical CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group phase III trial. Eur. J. Cancer, 27: 966–970, 1991.

Fisher B. , Dignam J. , Wolmark N. , De Cillis A. , Emir B. , Wickerham D.L. , Bryant J. , Dimitrov N.V. , Abramson N. , Atkins J.N. , Shibata H. , Deschenes L. , Margolese R.G. : Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl. Cancer Inst., 89: 1673–1682, 1997.

Henderson I.C. , Berry D. , Demetri G. , Cirrincione C. , Goldstein L. , Martino S. , Ingle J.N. , Cooper M.R. , Canellos G. , Borden E. , Fleming G. , Holland J.F. , Graziano S. , Carpenter J. , Muss H. , Norton L. , for CALGB, ECOG, SWOG, and NCCTG: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc. Am. Soc. Clin. Oncol., 17: A390, 1998.

Jakesz R. , Hausmaninger H. , Samonigg H. , Kubista E. , Depisch D. , Fridrik M. , Stierer M. , Gnant M. , Steger G. , Kolb R. , Katzko G. , Hofbauer F. , Reiner G. , Luschin-Ebengreuth G. : Comparison of adjuvant therapy with tamoxifen and goserelin versus CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group trial 5. Proc. Am. Soc. Clin. Oncol., 18: A250, 1999.

Levine M.N. , Bramwell V.H. , Pritchard K.I. , Norris B.D. , Shepherd L.E. , Abu-Zahra H. , Findlay B. , Warr D. , Bowman D. , Myles J. , Arnold A. , Vandenberg T. , MacKenzie R. , Robert J. , Ottaway J. , Burnell M. , Williams C.K. , Tu D. : Randomised trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. J. Clin. Oncol., 16: 2651–2658, 1998.

Mouridsen H.T. , Andersen J. , Andersson M. , Dombernowsky P. , Ejlertsen B. , Rose C. , Sorensen P.G. , Sandberg E. , Andersen K.W. , Jensen M.B. , Bengtson N.O. , Bergh J. , Nordenskjöld B. : Adjuvant anthracycline in breast cancer, improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc. Am. Soc. Clin. Oncol., 18: A254, 1999.

Peters W. , Rosner G. , Vredenburgh J. , Shpall E. , Crump M. , Richardson P. , Marks L. , Cirrincione C. , Wood W. , Henderson I. , Hurd D. , Norton L. for CALGB, SWOG, and NCIC: A prospective randomised comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc. Am. Soc. Clin. Oncol., 18: A2, 1999.

The Scandinavian Breast Cancer Study Group: Results from a randomised adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc. Am. Soc. Clin. Oncol., 18: A3, 1999.